Precigen Inc (NASDAQ:PGEN) — Market Cap & Net Worth
Market Cap & Net Worth: Precigen Inc (PGEN)
Precigen Inc (NASDAQ:PGEN) has a market capitalization of $1.50 Billion ($1.50 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7379 globally and #2177 in its home market, demonstrating a 34.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Precigen Inc's stock price $4.80 by its total outstanding shares 356510977 (356.51 Million). Review PGEN total debt and obligations to assess the company's total debt and financial obligations.
Precigen Inc Market Cap History: 2015 to 2026
Precigen Inc's market capitalization history from 2015 to 2026. Data shows change from $10.75 Billion to $1.71 Billion (-16.71% CAGR).
Index Memberships
Precigen Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.06% | #203 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.00% | #802 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.09% | #126 of 263 |
Weight: Precigen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Precigen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Precigen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
153.88x
Precigen Inc's market cap is 153.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $8.66 Billion | $190.93 Million | -$186.61 Million | 45.37x | N/A |
| 2017 | $4.11 Billion | $230.98 Million | -$117.02 Million | 17.78x | N/A |
| 2018 | $2.33 Billion | $160.57 Million | -$509.34 Million | 14.52x | N/A |
| 2019 | $1.95 Billion | $31.99 Million | -$170.52 Million | 61.07x | N/A |
| 2020 | $3.64 Billion | $31.99 Million | -$170.52 Million | 113.67x | N/A |
| 2021 | $1.32 Billion | $14.27 Million | -$92.17 Million | 92.71x | N/A |
| 2022 | $541.90 Million | $26.91 Million | $28.32 Million | 20.14x | 19.14x |
| 2023 | $477.72 Million | $6.22 Million | -$95.90 Million | 76.74x | N/A |
| 2024 | $399.29 Million | $3.92 Million | -$126.23 Million | 101.73x | N/A |
| 2025 | $1.49 Billion | $9.68 Million | -$250.64 Million | 153.88x | N/A |
Competitor Companies of PGEN by Market Capitalization
Companies near Precigen Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Precigen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Precigen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Precigen Inc's market cap moved from $10.75 Billion to $ 1.71 Billion, with a yearly change of -16.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.71 Billion | +14.83% |
| 2025 | $1.49 Billion | +273.21% |
| 2024 | $399.29 Million | -16.42% |
| 2023 | $477.72 Million | -11.84% |
| 2022 | $541.90 Million | -59.03% |
| 2021 | $1.32 Billion | -63.63% |
| 2020 | $3.64 Billion | +86.13% |
| 2019 | $1.95 Billion | -16.21% |
| 2018 | $2.33 Billion | -43.23% |
| 2017 | $4.11 Billion | -52.59% |
| 2016 | $8.66 Billion | -19.40% |
| 2015 | $10.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Precigen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more